Regeneron-backed oncolytic virus startup scores modest Series B extension

Paul Schloesser

Associate Editor

Three years ago, Regeneron collaborated with tiny, Rochester, MN biotech Vyriad to kickstart a Phase II trial. That collaboration deal would combine Regeneron’s PD-1 drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron-backed oncolytic virus startup scores modest Series B extension

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Re­gen­eron-backed on­colyt­ic virus start­up scores mod­est Se­ries B ex­ten­sion

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Regeneron-backed oncolytic virus startup scores modest Series B extension

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Food allergy biotech Alladapt closes after Phase 3 talks with FDA